Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy.
To evaluate the effects of parenteral cefoxitin therapy on human fecal flora, we cultured fecal specimens obtained from six patients before, during, and after therapy and used standard methods to identify and quantify all microorganisms. The major changes (observed in at least three patients) included the acquisition or proliferation of group D Streptococcus species, coagulase-negative Staphylococcus species, cefoxitin-resistant members of the family Enterobacteriaceae, Pseudomonas species, and various species of the Bacteroides fragilis group. The most striking finding was ingrowth of Clostridium difficile, noted in five of the six patients. There was concomitant eradication or decrease of cefoxitin-susceptible Enterobacteriaceae family members, Bacteroides species other than the B. fragilis group, Clostridium species other than C. difficile, and Lactobacillus species. These marked alterations of fecal flora may have important clinical consequences.
D000328:Adult; D001419:Bacteria / Q000187:drug effects*; D002440:Cefoxitin / Q000494:pharmacology*; D003013:Clostridium / Q000187:drug effects* / Q000254:growth & development; D005243:Feces / Q000382:microbiology*; D006801:Humans; D008297:Male
D002440:Cefoxitin